SYS-6002 is under clinical development by Corbus Pharmaceuticals and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 37% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how SYS-6002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SYS-6002 overview
SYS-6002 is under development for the treatment of advanced solid tumors, metastatic urothelial carcinoma, cervical cancer, prostate cancer and triple-negative breast cancer. The therapeutic candidate is a next-generation antibody-drug-conjugate (ADC) that contains a site-specific, cleavable linker and a homogenous drug antibody ratio of 2 and monomethyl auristatin E (MMAE) as the payload. It is administered through parenteral and intravenous route. It acts by targeting nectin 4.
Corbus Pharmaceuticals overview
Corbus Pharmaceuticals is a clinical-stage pharmaceutical company that develops and commercializes novel therapeutics to treat inflammatory and fibrotic diseases. The company’s pipeline product portfolio includes Lenabasum, an oral small-molecule for the treatment of inflammatory diseases; CRB-4001, to treat fibrotic diseases. It serves in the therapeutic areas of chronic inflammation, autoimmune diseases, allergies and orphan diseases. Corbus Pharmaceuticals collaborates with National Institutes of Health (NIH) for in the development of drugs. The company operates in the UK and Australia. Corbus Pharmaceuticals is headquartered in Norwood, Massachusetts, the US.
For a complete picture of SYS-6002’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
